Risk Factors Associated with the Severity of Thyroid-Associated Orbitopathy in Korean Patients
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The purpose of this study is to identify risk factors for severe thyroid-associated orbitopathy (TAO) and compressive optic neuropathy in Korean patients. Methods: This study was a retrospective comparative case series. All TAO patients who were first seen at our institution between 2005 and 2009 and who had follow-up periods of at least 6 months were included. Patients were divided into mild or moderate and severe TAO groups. Cases were also segregated based on the presence or absence of optic neuropathy. Demographics, smoking status, comorbidities, thyroid hormonal status, thyroid autoantibody levels, and clinical presentations were assessed. Results: A total of 99 patients (83 with mild to moderate courses and 16 with severe courses; 90 without optic neuropathy and 9 with optic neuropathy) were included in this study. On multiple logistic regression analysis, smoking status was a predictive risk factor for a severe course of TAO and the development of optic neuropathy (odds ratios = 6.57 and 10.00, respectively). Other factors such as age, gender, free T4 level, thyroid binding-inhibiting immunoglobulin, and a history of diabetes were not predictive of severe TAO or optic neuropathy. Conclusions: Although various factors may influence the severity of TAO and the development of optic neuropathy,this study showed that smoking was a risk factor for severe TAO and the development of optic neuropathy. Therefore, it is important for patients with Graves’ disease to refrain from smoking. Frequent and careful observation should also be performed in current smokers, as TAO patients who smoke are susceptible to a severe course and/or optic neuropathy.
Abstract
Purpose: The purpose of this study is to identify risk factors for severe thyroid-associated orbitopathy (TAO) and compressive optic neuropathy in Korean patients. Methods: This study was a retrospective comparative case series. All TAO patients who were first seen at our institution between 2005 and 2009 and who had follow-up periods of at least 6 months were included. Patients were divided into mild or moderate and severe TAO groups. Cases were also segregated based on the presence or absence of optic neuropathy. Demographics, smoking status, comorbidities, thyroid hormonal status, thyroid autoantibody levels, and clinical presentations were assessed. Results: A total of 99 patients (83 with mild to moderate courses and 16 with severe courses; 90 without optic neuropathy and 9 with optic neuropathy) were included in this study. On multiple logistic regression analysis, smoking status was a predictive risk factor for a severe course of TAO and the development of optic neuropathy (odds ratios = 6.57 and 10.00, respectively). Other factors such as age, gender, free T4 level, thyroid binding-inhibiting immunoglobulin, and a history of diabetes were not predictive of severe TAO or optic neuropathy. Conclusions: Although various factors may influence the severity of TAO and the development of optic neuropathy,this study showed that smoking was a risk factor for severe TAO and the development of optic neuropathy. Therefore, it is important for patients with Graves’ disease to refrain from smoking. Frequent and careful observation should also be performed in current smokers, as TAO patients who smoke are susceptible to a severe course and/or optic neuropathy.
참고문헌 (32)
- Bartalena L, "Management of Graves’ ophthalmopathy: reality and perspectives", Endocr Rev, 21, pp.168~199 (2000)
- Bartley GB, "Long-term follow- up of Graves ophthalmopathy in an incidence cohort", Ophthalmology, 103, pp.958~962 (1996)
- Bartalena L, "Graves’ ophthalmopathy: a preventable disease?", Eur J Endocrinol, 146, pp.457~461 (2002)
- Wiersinga WM, "Epidemiology and prevention of Graves’ ophthalmopathy", Thyroid, 12, pp.855~860 (2002)
- Kim JM, "The relation of Graves’ ophthalmopathy to circulating thyroid hormone status", Br J Ophthalmol, 88, pp.72~74 (2004)
- Prummel MF, "Smoking and risk of Graves’ disease", JAMA, 269, pp.479~482 (1993)
- Prummel MF, "Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy", Arch Intern Med, 150, pp.1098~1101 (1990)
- Tallstedt L, "Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group", N Engl J Med, 326, pp.1733~1738 (1992)
- Wiersinga WM, "Management of Graves’ ophthalmopathy", Nat Clin Pract Endocrinol Metab, 3, pp.396~404 (2007)
- Bahn RS, "Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy", Endocrinol Metab Clin North Am, 16, pp.391~407 (1987)
- Mourits MP, "Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy", Clin Endocrinol (Oxf), 47, pp.9~14 (1997)
- "Classification of eye changes of Graves’ disease", Thyroid, 2, pp.235~236 (1992)
- Kahaly GJ, "Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy", J Clin Endocrinol Metab, 90, pp.5234~5240 (2005)
- Perros P, "Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic", Clin Endocrinol (Oxf), 38, pp.367~372 (1993)
- Tallstedt L, "Graves’ ophthalmopathy and tobacco smoking", Acta Endocrinol (Copenh, 129, pp.147~150 (1993)
- Winsa B, "Graves’ disease, endocrine ophthalmopathy and smoking", Acta Endocrinol (Copenh), 128, pp.156~160 (1993)
- Thornton J, "Cigarette smoking and thyroid eye disease: a systematic review", Eye (Lond), 21, pp.1135~1145 (2007)
- Pfeilschifter J, "Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption", Clin Endocrinol (Oxf), 45, pp.477~481 (1996)
- Bartalena L, "Cigarette smoking and treatment outcomes in Graves ophthalmopathy", Ann Intern Med, 129, pp.632~635 (1998)
- Solomon DH, "Identification of subgroups of euthyroid Graves’ ophthalmopathy", N Engl J Med, 296, pp.181~186 (1977)
- Bhatnagar A, "Graves’ orbitopathy", Ophthalmology, 114, pp.392~ (2007)
- Petersen IA, "Donaldson SS. Prognostic factors in the radiotherapy of Graves’ ophthalmopathy", Int J Radiat Oncol Biol Phys, 19, pp.259~264 (1990)
- Dayan CM, "Dysthyroid optic neuropathy: a clinical diagnosis or a definable entity?", Br J Ophthalmol, 91, pp.409~410 (2007)
- Bartalena L, "Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy", Thyroid, 18, pp.333~346 (2008)
- Soares-Welch CV, "Optic neuropathy of Graves disease: results of transantral orbital decompression and long-term follow-up in 215 patients", Am J Ophthalmol, 136, pp.433~441 (2003)
- Feldon SE, "Clinical classification of Graves’ ophthalmopathy. Identification of risk factors for optic neuropathy", Arch Ophthalmol, 102, pp.1469~1472 (1984)
- Mouritz MP, "Reliability of exophthalmos measurement and the exophthalmometry value distribution in a healthy Dutch population and in Graves’ patients. An exploratory study", Orbit, 23, pp.161~168 (2004)
- McKeag D, "Clinical features of dysthyroid optic neuropathy: a European Group on Graves’ Orbitopathy (EUGOGO) survey", Br J Ophthalmol, 91, pp.455~458 (2007)
- Burch HB, "Graves’ ophthalmopathy: current concepts regarding pathogenesis and management", Endocr Rev, 14, pp.747~793 (1993)
- Khoo DH, "The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves’ disease identifies a group at markedly increased risk of ophthalmopathy", Thyroid, 9, pp.1175~1180 (1999)
- Gerding MN, "Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy", Clin Endocrinol (Oxf), 52, pp.267~271 (2000)
- Cawood TJ, "Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link", J Clin Endocrinol Metab, 92, pp.59~64 (2007)